ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113),in patients with anaplastic lymphoma kinase positive (ALK+) …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), today announced that Health Canada has approved the use of Iclusig™ (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all …
Recently, various executives have taken part in insider selling activity for the stocks of QUALCOMM, Inc. (NASDAQ:QCOM), Pandora Media Inc (NYSE:P), Ariad Pharmaceuticals, …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late …
In a research report released on Monday, H.C.
Cowen’s healthcare analyst Phil Nadeau came out with a research note on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), following the company’s earnings release for the fourth-quarter.
J.P.
(BUSINESS WIRE)–Jan. 29, 2015– ARIAD Pharmaceuticals, Inc.
(BUSINESS WIRE)–Jan. 22, 2015– ARIAD Pharmaceuticals, Inc.
(BUSINESS WIRE)–Jan. 20, 2015– ARIAD Pharmaceuticals, Inc.
